Details
Stereochemistry | ACHIRAL |
Molecular Formula | C5H11NO2 |
Molecular Weight | 117.1463 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
C[N+](C)(C)CC([O-])=O
InChI
InChIKey=KWIUHFFTVRNATP-UHFFFAOYSA-N
InChI=1S/C5H11NO2/c1-6(2,3)4-5(7)8/h4H2,1-3H3
Betaine is a methyl derivative of glycine first isolated from the juice of sugar beets. Betaine is found in many common foods, but concentrated significantly in beets, spinach, wheat foods, and shellfish. In addition, betaine can be synthesized within the human body. Betaine participates in the methionine cycle, which produces vital biomolecules including proteins, hormones, phospholipids, polyamines, and nutrients. Betaine is used as a dietary supplement and has a beneficial effect on the human health. In the USA, FDA approved a betaine-containing drug Cystadane for the treatment of homocystinuria. The drug acts as a methyl group donor in the remethylation of homocysteine to methionine.
CNS Activity
Approval Year
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | CYSTADANE Approved UseCystadane is a methylating agent indicated for the treatment of homocystinuria to decrease elevated homocysteine blood levels. Included within the category of homocystinuria are Cystathionine beta-synthase (CBS) deficiency, 5,10-methylenetetrahydrofolate reductase (MTHFR) deficiency, Cobalamin cofactor metabolism (cbl) defect. Launch Date1996 |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
1.456 mM EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/12534635 |
50 mg/kg bw 2 times / day multiple, oral dose: 50 mg/kg bw route of administration: Oral experiment type: MULTIPLE co-administered: |
BETAINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
0.939 mM EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/12534635 |
50 mg/kg bw single, oral dose: 50 mg/kg bw route of administration: Oral experiment type: SINGLE co-administered: |
BETAINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
12.528 mM × h EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/12534635 |
50 mg/kg bw 2 times / day multiple, oral dose: 50 mg/kg bw route of administration: Oral experiment type: MULTIPLE co-administered: |
BETAINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
5.518 mM × h EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/12534635 |
50 mg/kg bw single, oral dose: 50 mg/kg bw route of administration: Oral experiment type: SINGLE co-administered: |
BETAINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
41.17 h EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/12534635 |
50 mg/kg bw 2 times / day multiple, oral dose: 50 mg/kg bw route of administration: Oral experiment type: MULTIPLE co-administered: |
BETAINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
14.38 h EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/12534635 |
50 mg/kg bw single, oral dose: 50 mg/kg bw route of administration: Oral experiment type: SINGLE co-administered: |
BETAINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
PubMed
Title | Date | PubMed |
---|---|---|
The clinical potential of ademetionine (S-adenosylmethionine) in neurological disorders. | 1994 Aug |
|
Strychnine-dependent allodynia in the urethane-anesthetized rat is segmentally distributed and prevented by intrathecal glycine and betaine. | 1995 Dec |
|
Cerebrospinal fluid and plasma total homocysteine and related metabolites in children with cystathionine beta-synthase deficiency: the effect of treatment. | 1997 Nov |
|
Simple method for the routine determination of betaine and N,N-dimethylglycine in blood and urine. | 1998 Sep |
|
An open-label, 24-week pilot study of the methyl donor betaine in Alzheimer disease patients. | 2001 Jul-Sep |
|
Carbon tetrachloride-induced nephrotoxicity and protective effect of betaine in Sprague-Dawley rats. | 2003 Aug |
|
Homocysteine-betaine interactions in a murine model of 5,10-methylenetetrahydrofolate reductase deficiency. | 2003 Mar |
|
Betaine suppresses proinflammatory signaling during aging: the involvement of nuclear factor-kappaB via nuclear factor-inducing kinase/IkappaB kinase and mitogen-activated protein kinases. | 2005 Oct |
|
Mechanism of the inhibitory effect of zwitterionic drugs (levofloxacin and grepafloxacin) on carnitine transporter (OCTN2) in Caco-2 cells. | 2006 Nov |
|
Betaine-homocysteine S-methyltransferase-2 is an S-methylmethionine-homocysteine methyltransferase. | 2008 Apr 4 |
|
Alleviation of dimethylnitrosamine-induced liver injury and fibrosis by betaine supplementation in rats. | 2009 Feb 12 |
|
S-Adenosylhomocysteine increases beta-amyloid formation in BV-2 microglial cells by increased expressions of beta-amyloid precursor protein and presenilin 1 and by hypomethylation of these gene promoters. | 2009 Jul |
|
Identification of a novel organic anion transporter mediating carnitine transport in mouse liver and kidney. | 2010 |
|
A urinary metabonomics study on biochemical changes in yeast-induced pyrexia rats: a new approach to elucidating the biochemical basis of the febrile response. | 2013 Jun 25 |
|
The organic osmolyte betaine induces keratin 2 expression in rat epidermal keratinocytes - A genome-wide study in UVB irradiated organotypic 3D cultures. | 2015 Dec 25 |
|
Betanin reduces the accumulation and cross-links of collagen in high-fructose-fed rat heart through inhibiting non-enzymatic glycation. | 2015 Feb 5 |
Patents
Sample Use Guides
The usual dosage in adult and pediatric patients is 6 grams per day administered orally in divided doses of 3 grams twice daily. In pediatric patients less than 3 years of age, dosage may be started at 100 mg/kg/day divided in twice daily doses, and then increased weekly by 50 mg/kg increments.
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/25921120
HeLa cells were treated with 0.1, 1.0, 5.0, 20.0, 100.0 mg/ml of betaine to evaluate the anticancer efficacy of the compound. The percentage of S phase cells in the low dose groups (< 5mg/ml) were distinctly higher than in high dose groups, and the rates of Sub-G1 phase were the opposite. A high concentration of betaine (>5.0mg/ml) significantly promoted the apoptosis of HeLa cells.
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
EPA PESTICIDE CODE |
103669
Created by
admin on Fri Dec 15 15:10:14 GMT 2023 , Edited by admin on Fri Dec 15 15:10:14 GMT 2023
|
||
|
FDA ORPHAN DRUG |
81794
Created by
admin on Fri Dec 15 15:10:14 GMT 2023 , Edited by admin on Fri Dec 15 15:10:14 GMT 2023
|
||
|
NDF-RT |
N0000175805
Created by
admin on Fri Dec 15 15:10:14 GMT 2023 , Edited by admin on Fri Dec 15 15:10:14 GMT 2023
|
||
|
NDF-RT |
N0000175804
Created by
admin on Fri Dec 15 15:10:14 GMT 2023 , Edited by admin on Fri Dec 15 15:10:14 GMT 2023
|
||
|
EMA ASSESSMENT REPORTS |
XIAPEX (AUTHORIZED DUPUYTREN CONTRACTURE)
Created by
admin on Fri Dec 15 15:10:14 GMT 2023 , Edited by admin on Fri Dec 15 15:10:14 GMT 2023
|
||
|
EMA ASSESSMENT REPORTS |
CYSTADANE (AUTHORIZED HOMOCYSTINURIA)
Created by
admin on Fri Dec 15 15:10:14 GMT 2023 , Edited by admin on Fri Dec 15 15:10:14 GMT 2023
|
||
|
DSLD |
2312 (Number of products:649)
Created by
admin on Fri Dec 15 15:10:14 GMT 2023 , Edited by admin on Fri Dec 15 15:10:14 GMT 2023
|
||
|
WHO-ATC |
A16AA06
Created by
admin on Fri Dec 15 15:10:14 GMT 2023 , Edited by admin on Fri Dec 15 15:10:14 GMT 2023
|
||
|
WHO-ATC |
A09AB02
Created by
admin on Fri Dec 15 15:10:14 GMT 2023 , Edited by admin on Fri Dec 15 15:10:14 GMT 2023
|
||
|
EU-Orphan Drug |
EU/3/01/045
Created by
admin on Fri Dec 15 15:10:14 GMT 2023 , Edited by admin on Fri Dec 15 15:10:14 GMT 2023
|
||
|
WHO-VATC |
QA16AA06
Created by
admin on Fri Dec 15 15:10:14 GMT 2023 , Edited by admin on Fri Dec 15 15:10:14 GMT 2023
|
||
|
DSLD |
625 (Number of products:495)
Created by
admin on Fri Dec 15 15:10:14 GMT 2023 , Edited by admin on Fri Dec 15 15:10:14 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
203-490-6
Created by
admin on Fri Dec 15 15:10:14 GMT 2023 , Edited by admin on Fri Dec 15 15:10:14 GMT 2023
|
PRIMARY | |||
|
247
Created by
admin on Fri Dec 15 15:10:14 GMT 2023 , Edited by admin on Fri Dec 15 15:10:14 GMT 2023
|
PRIMARY | |||
|
1065695
Created by
admin on Fri Dec 15 15:10:14 GMT 2023 , Edited by admin on Fri Dec 15 15:10:14 GMT 2023
|
PRIMARY | |||
|
D001622
Created by
admin on Fri Dec 15 15:10:14 GMT 2023 , Edited by admin on Fri Dec 15 15:10:14 GMT 2023
|
PRIMARY | |||
|
C81038
Created by
admin on Fri Dec 15 15:10:14 GMT 2023 , Edited by admin on Fri Dec 15 15:10:14 GMT 2023
|
PRIMARY | |||
|
347
Created by
admin on Fri Dec 15 15:10:14 GMT 2023 , Edited by admin on Fri Dec 15 15:10:14 GMT 2023
|
PRIMARY | |||
|
C1505
Created by
admin on Fri Dec 15 15:10:14 GMT 2023 , Edited by admin on Fri Dec 15 15:10:14 GMT 2023
|
CONCEPT | Dietary Supplement | ||
|
350374
Created by
admin on Fri Dec 15 15:10:14 GMT 2023 , Edited by admin on Fri Dec 15 15:10:14 GMT 2023
|
PRIMARY | |||
|
107-43-7
Created by
admin on Fri Dec 15 15:10:14 GMT 2023 , Edited by admin on Fri Dec 15 15:10:14 GMT 2023
|
PRIMARY | |||
|
3SCV180C9W
Created by
admin on Fri Dec 15 15:10:14 GMT 2023 , Edited by admin on Fri Dec 15 15:10:14 GMT 2023
|
PRIMARY | |||
|
17750
Created by
admin on Fri Dec 15 15:10:14 GMT 2023 , Edited by admin on Fri Dec 15 15:10:14 GMT 2023
|
PRIMARY | |||
|
7467
Created by
admin on Fri Dec 15 15:10:14 GMT 2023 , Edited by admin on Fri Dec 15 15:10:14 GMT 2023
|
PRIMARY | |||
|
3SCV180C9W
Created by
admin on Fri Dec 15 15:10:14 GMT 2023 , Edited by admin on Fri Dec 15 15:10:14 GMT 2023
|
PRIMARY | |||
|
1512
Created by
admin on Fri Dec 15 15:10:14 GMT 2023 , Edited by admin on Fri Dec 15 15:10:14 GMT 2023
|
ALTERNATIVE | |||
|
SUB13055MIG
Created by
admin on Fri Dec 15 15:10:14 GMT 2023 , Edited by admin on Fri Dec 15 15:10:14 GMT 2023
|
PRIMARY | |||
|
SUB23574
Created by
admin on Fri Dec 15 15:10:14 GMT 2023 , Edited by admin on Fri Dec 15 15:10:14 GMT 2023
|
PRIMARY | |||
|
166511
Created by
admin on Fri Dec 15 15:10:14 GMT 2023 , Edited by admin on Fri Dec 15 15:10:14 GMT 2023
|
PRIMARY | |||
|
m2451
Created by
admin on Fri Dec 15 15:10:14 GMT 2023 , Edited by admin on Fri Dec 15 15:10:14 GMT 2023
|
PRIMARY | Merck Index | ||
|
100000089335
Created by
admin on Fri Dec 15 15:10:14 GMT 2023 , Edited by admin on Fri Dec 15 15:10:14 GMT 2023
|
PRIMARY | |||
|
TRIMETHYLGLYCINE
Created by
admin on Fri Dec 15 15:10:14 GMT 2023 , Edited by admin on Fri Dec 15 15:10:14 GMT 2023
|
PRIMARY | |||
|
DTXSID8022666
Created by
admin on Fri Dec 15 15:10:14 GMT 2023 , Edited by admin on Fri Dec 15 15:10:14 GMT 2023
|
PRIMARY | |||
|
DB06756
Created by
admin on Fri Dec 15 15:10:14 GMT 2023 , Edited by admin on Fri Dec 15 15:10:14 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
SALT/SOLVATE (PARENT)
SALT/SOLVATE (PARENT)
SALT/SOLVATE (PARENT)
SALT/SOLVATE (PARENT)
SALT/SOLVATE (PARENT)